⌘K
Loading ticker…
As of 2026-08-24, Vistagen Therapeutics, Inc. Common Stock (VTGN) has a 3-month relative strength percentile of 4 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 26. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 8.5%, relative volume 0.07×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
VTGN is in a stage 4 downtrend, week 8. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -28.0% / -77.3%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
VTGN is held by 3 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $663K notional. Top 3 carry $1M.
Held by 4 ETFs · $1M across latest filings · largest weight 0.78% (PSIL).
Top 3 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $663K | — |
| VXFVanguard Extended Market ETF | 0.00% | $236K | — |
| PSIL | 0.78% | $158K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | VTGN Jan avg: 31.64% median: -4.52% win: 25% σ: 79.95% n: 4 2022-04-12 → 2026-07-31 | VTGN Feb avg: -6.71% median: -0.80% win: 50% σ: 17.97% n: 4 2022-04-12 → 2026-07-31 | VTGN Mar avg: -8.88% median: -4.94% win: 25% σ: 14.10% n: 4 2022-04-12 → 2026-07-31 | VTGN Apr avg: 0.03% median: -4.51% win: 40% σ: 9.20% n: 5 2022-04-12 → 2026-07-31 | VTGN May avg: -3.01% median: 1.50% win: 60% σ: 11.85% n: 5 2022-04-12 → 2026-07-31 | VTGN Jun avg: -35.21% median: -23.48% win: 0% σ: 23.54% n: 5 2022-04-12 → 2026-07-31 | VTGN Jul avg: -7.54% median: -1.44% win: 40% σ: 46.56% n: 5 2022-04-12 → 2026-07-31 | VTGN Aug avg: 59.89% median: 22.48% win: 100% σ: 89.32% n: 4 2022-04-12 → 2026-07-31 (current) | VTGN Sep avg: -6.62% median: -7.72% win: 25% σ: 10.90% n: 4 2022-04-12 → 2026-07-31 | VTGN Oct avg: -9.71% median: -5.25% win: 50% σ: 22.05% n: 4 2022-04-12 → 2026-07-31 | VTGN Nov avg: 8.40% median: 8.52% win: 75% σ: 13.61% n: 4 2022-04-12 → 2026-07-31 | VTGN Dec avg: -16.21% median: -10.77% win: 50% σ: 54.63% n: 4 2022-04-12 → 2026-07-31 |